Tempus AI Launches Digital Pathology Open-Source Consortium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- Consortium Formation: Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center have launched the digital pathology IMS Open-Source Consortium, aimed at accelerating the democratization and standardization of digital pathology to promote widespread clinical adoption.
- Technology Sharing: Tempus will open source its existing Paige Image Management System, including the slide viewer and case management solutions, thereby providing clinical-grade digital pathology baseline solutions to institutions globally, enhancing the application potential of pathology.
- Industry Collaboration: As founding members, YNHH and MSK will collaboratively define the vision and strategic direction of the open-source ecosystem, fostering cooperation between academia and industry partners to drive an open, scalable, and interoperable digital pathology environment.
- Growing Market Demand: With rising demand for diagnostic and biomarker testing, digital pathology presents a unique opportunity to optimize tissue utilization and improve laboratory workflows, and Tempus looks forward to enhancing patient care quality through this consortium.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 52.260
Low
76.00
Averages
84.38
High
105.00
Current: 52.260
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempus AI Launches Digital Pathology Open-Source Consortium
- Consortium Formation: Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center have launched the digital pathology IMS Open-Source Consortium, aimed at accelerating the democratization and standardization of digital pathology to promote widespread clinical adoption.
- Technology Sharing: Tempus will open source its existing Paige Image Management System, including the slide viewer and case management solutions, thereby providing clinical-grade digital pathology baseline solutions to institutions globally, enhancing the application potential of pathology.
- Industry Collaboration: As founding members, YNHH and MSK will collaboratively define the vision and strategic direction of the open-source ecosystem, fostering cooperation between academia and industry partners to drive an open, scalable, and interoperable digital pathology environment.
- Growing Market Demand: With rising demand for diagnostic and biomarker testing, digital pathology presents a unique opportunity to optimize tissue utilization and improve laboratory workflows, and Tempus looks forward to enhancing patient care quality through this consortium.
See More
AstraZeneca CEO Discusses AI's Role in Drug Development
- AI Enhances R&D Efficiency: AstraZeneca CEO Pascal Soriot stated that artificial intelligence is accelerating the drug development process, enabling faster and smarter design of new medicines, thereby improving productivity to meet urgent market demands.
- Optimizing Drug Design: With AI technology, AstraZeneca can identify new targets and optimize molecular structures by removing potential side effects, which not only enhances drug safety but also increases the likelihood of successful development, holding significant competitive market implications.
- Data-Driven Decision Making: The partnership with Tempus AI allows AstraZeneca to leverage AI models to analyze clinical and laboratory data, thereby better predicting the success probability of Phase 3 trials, reducing development risks and enhancing investment returns.
- Significant Economic Benefits: Soriot highlighted that drug trials typically cost between $300 million and $500 million, and by increasing the probability of success, the application of AI will yield enormous productivity improvements, significantly enhancing the company's financial performance.
See More
Tempus AI Launches Next-Generation Genetic Test for Oncology
- Clinical Availability Boost: Tempus AI announces the upcoming launch of the xH test, which utilizes whole-genome sequencing to detect actionable oncologic targets in blood and bone marrow samples, expected to significantly enhance diagnostic efficiency for patients with hematologic malignancies.
- Validation Study Results: In an analytical validation study involving 235 unique specimens, the xH test achieved a positive percent agreement of 97.29% for SNVs and Indels, demonstrating high accuracy across multiple variant classes and bolstering confidence in its clinical application.
- Sensitivity and Discovery Rate: In a blinded study of an MDS cohort, the xH test achieved over 99% sensitivity and uncovered more than 40% of clinically relevant genomic variations that were missed by traditional methods, highlighting its superiority in guiding clinical decisions.
- Strategic Goal Achievement: Tempus CEO Tom Schonherr stated that the launch of the xH test marks the realization of the company's vision in hematologic oncology, streamlining diagnostic processes to enable faster decision-making for clinicians while providing biopharma partners with a multiomic foundation to enhance clinical trial design and targeted therapy development.
See More
Tempus Launches Next-Gen AI Platform Lens to Accelerate Drug Development
- Platform Upgrade: The next-generation Lens platform launched by Tempus integrates over a decade of real-world data and AI tools, aiming to accelerate drug development and significantly enhance research efficiency for biopharma companies.
- User Base Expansion: The Lens platform is currently utilized by 19 of the top 20 biopharma companies globally, indicating its widespread recognition and application potential in the industry, further solidifying Tempus's leadership in precision medicine.
- Intelligent Analysis Tools: The new platform offers custom research plan generation and on-demand execution features, allowing users to propose complex hypotheses in natural language and quickly receive targeted analysis plans, thereby reducing clinical trial design time and improving decision-making efficiency.
- Transparency and Reproducibility: Results from the Lens platform are presented through interactive applications and reports, with users able to toggle to a
See More
Tempus Launches PRECISION Challenge to Accelerate Oncology Breakthroughs
- Innovative Challenge Program: Tempus has launched the PRECISION Challenge, aimed at accelerating breakthroughs in oncology by providing funding, data, and expertise to multidisciplinary teams worldwide, which is expected to significantly enhance cancer treatment outcomes.
- Resource Support: The program offers participants up to $75,000 in funding and computational resources to support various stages from proof of concept to clinical performance validation, ensuring that funding is closely tied to research progress.
- Data Access: Participants will gain access to Tempus' de-identified data library, one of the world's largest repositories of clinical, molecular, and imaging data, combined with Tempus' foundational models and computational infrastructure to facilitate biological discovery.
- Future Outlook: Tempus plans to open applications in the coming months, encouraging researchers to seize this unprecedented opportunity to address critical issues in oncology and advance precision medicine.
See More
Tempus AI Launches Rapid Clinical Insights Application
- Breakthrough in Precision Medicine: Tempus AI's newly launched Tempus Preview application provides key mutation predictions within approximately 24 hours of tissue receipt, significantly reducing the time between diagnostic test orders and final results, enabling faster treatment decisions during the critical early stages following a cancer diagnosis.
- Focus on High-Impact Biomarkers: The application targets early insights into high-impact biomarkers such as microsatellite instability (MSI-H) and EGFR mutations, enhancing predictions for responses to immune checkpoint inhibitors and targeted therapies, thereby improving patient prognosis.
- AI-Driven Precision Analysis: Powered by the Paige Predict model, Tempus Preview analyzes standard H&E images to deliver genomic insights, having been validated for clinical use after training on millions of slides, which further strengthens Tempus's competitive edge in the precision medicine sector.
- Strategic Data Integration: By combining its unique diagnostic lab with an advanced data platform, Tempus creates powerful AI models that deliver early, clinically relevant information directly into clinical workflows, assisting physicians in making more informed decisions in patient treatment.
See More
Tempus AI Launches Digital Pathology Open-Source Consortium
- Consortium Formation: Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center have launched the digital pathology IMS Open-Source Consortium, aimed at accelerating the democratization and standardization of digital pathology to promote widespread clinical adoption.
- Technology Sharing: Tempus will open source its existing Paige Image Management System, including the slide viewer and case management solutions, thereby providing clinical-grade digital pathology baseline solutions to institutions globally, enhancing the application potential of pathology.
- Industry Collaboration: As founding members, YNHH and MSK will collaboratively define the vision and strategic direction of the open-source ecosystem, fostering cooperation between academia and industry partners to drive an open, scalable, and interoperable digital pathology environment.
- Growing Market Demand: With rising demand for diagnostic and biomarker testing, digital pathology presents a unique opportunity to optimize tissue utilization and improve laboratory workflows, and Tempus looks forward to enhancing patient care quality through this consortium.
See More
AstraZeneca CEO Discusses AI's Role in Drug Development
- AI Enhances R&D Efficiency: AstraZeneca CEO Pascal Soriot stated that artificial intelligence is accelerating the drug development process, enabling faster and smarter design of new medicines, thereby improving productivity to meet urgent market demands.
- Optimizing Drug Design: With AI technology, AstraZeneca can identify new targets and optimize molecular structures by removing potential side effects, which not only enhances drug safety but also increases the likelihood of successful development, holding significant competitive market implications.
- Data-Driven Decision Making: The partnership with Tempus AI allows AstraZeneca to leverage AI models to analyze clinical and laboratory data, thereby better predicting the success probability of Phase 3 trials, reducing development risks and enhancing investment returns.
- Significant Economic Benefits: Soriot highlighted that drug trials typically cost between $300 million and $500 million, and by increasing the probability of success, the application of AI will yield enormous productivity improvements, significantly enhancing the company's financial performance.
See More
Tempus AI Launches Next-Generation Genetic Test for Oncology
- Clinical Availability Boost: Tempus AI announces the upcoming launch of the xH test, which utilizes whole-genome sequencing to detect actionable oncologic targets in blood and bone marrow samples, expected to significantly enhance diagnostic efficiency for patients with hematologic malignancies.
- Validation Study Results: In an analytical validation study involving 235 unique specimens, the xH test achieved a positive percent agreement of 97.29% for SNVs and Indels, demonstrating high accuracy across multiple variant classes and bolstering confidence in its clinical application.
- Sensitivity and Discovery Rate: In a blinded study of an MDS cohort, the xH test achieved over 99% sensitivity and uncovered more than 40% of clinically relevant genomic variations that were missed by traditional methods, highlighting its superiority in guiding clinical decisions.
- Strategic Goal Achievement: Tempus CEO Tom Schonherr stated that the launch of the xH test marks the realization of the company's vision in hematologic oncology, streamlining diagnostic processes to enable faster decision-making for clinicians while providing biopharma partners with a multiomic foundation to enhance clinical trial design and targeted therapy development.
See More
Tempus Launches Next-Gen AI Platform Lens to Accelerate Drug Development
- Platform Upgrade: The next-generation Lens platform launched by Tempus integrates over a decade of real-world data and AI tools, aiming to accelerate drug development and significantly enhance research efficiency for biopharma companies.
- User Base Expansion: The Lens platform is currently utilized by 19 of the top 20 biopharma companies globally, indicating its widespread recognition and application potential in the industry, further solidifying Tempus's leadership in precision medicine.
- Intelligent Analysis Tools: The new platform offers custom research plan generation and on-demand execution features, allowing users to propose complex hypotheses in natural language and quickly receive targeted analysis plans, thereby reducing clinical trial design time and improving decision-making efficiency.
- Transparency and Reproducibility: Results from the Lens platform are presented through interactive applications and reports, with users able to toggle to a
See More
Tempus Launches PRECISION Challenge to Accelerate Oncology Breakthroughs
- Innovative Challenge Program: Tempus has launched the PRECISION Challenge, aimed at accelerating breakthroughs in oncology by providing funding, data, and expertise to multidisciplinary teams worldwide, which is expected to significantly enhance cancer treatment outcomes.
- Resource Support: The program offers participants up to $75,000 in funding and computational resources to support various stages from proof of concept to clinical performance validation, ensuring that funding is closely tied to research progress.
- Data Access: Participants will gain access to Tempus' de-identified data library, one of the world's largest repositories of clinical, molecular, and imaging data, combined with Tempus' foundational models and computational infrastructure to facilitate biological discovery.
- Future Outlook: Tempus plans to open applications in the coming months, encouraging researchers to seize this unprecedented opportunity to address critical issues in oncology and advance precision medicine.
See More
Tempus AI Launches Rapid Clinical Insights Application
- Breakthrough in Precision Medicine: Tempus AI's newly launched Tempus Preview application provides key mutation predictions within approximately 24 hours of tissue receipt, significantly reducing the time between diagnostic test orders and final results, enabling faster treatment decisions during the critical early stages following a cancer diagnosis.
- Focus on High-Impact Biomarkers: The application targets early insights into high-impact biomarkers such as microsatellite instability (MSI-H) and EGFR mutations, enhancing predictions for responses to immune checkpoint inhibitors and targeted therapies, thereby improving patient prognosis.
- AI-Driven Precision Analysis: Powered by the Paige Predict model, Tempus Preview analyzes standard H&E images to deliver genomic insights, having been validated for clinical use after training on millions of slides, which further strengthens Tempus's competitive edge in the precision medicine sector.
- Strategic Data Integration: By combining its unique diagnostic lab with an advanced data platform, Tempus creates powerful AI models that deliver early, clinically relevant information directly into clinical workflows, assisting physicians in making more informed decisions in patient treatment.
See More
